S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Five Prime TherapeuticsCalithera BiosciencesCytoDynCerecorKala Pharmaceuticals
SymbolNASDAQ:FPRXNASDAQ:CALAOTCMKTS:CYDYNASDAQ:CERCNASDAQ:KALA
Price Information
Current Price$3.99$2.69$0.31$3.39$3.48
52 Week RangeHoldBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$15.00$8.00$1.00$9.67$21.80
% Upside from Price Target275.94% upside197.40% upside222.58% upside185.15% upside526.44% upside
Trade Information
Market Cap$151.91 million$145.44 million$107.40 million$153.05 million$118.70 million
Beta2.571.830.632.112.14
Average Volume372,270288,492415,248118,242246,675
Sales & Book Value
Annual Revenue$49.87 million$22.25 millionN/A$18.33 millionN/A
Price / Sales2.946.50N/A8.16N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$7.48 per share$3.32 per share($0.02) per share$0.51 per share$3.11 per share
Price / Book0.530.81N/A6.65N/A
Profitability
Net Income$-140,450,000.00$-54,630,000.00$-56,190,000.00$-40,050,000.00$-66,740,000.00
EPS($4.13)($1.49)($0.21)N/A($2.48)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/A1.63N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-842.84%N/AN/A-231.68%N/A
Return on Equity (ROE)-62.13%-67.87%N/A-143.30%-117.68%
Return on Assets (ROA)-48.06%-58.56%-289.37%-42.73%-52.43%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.23%N/AN/A0.81%1.16%
Current Ratio6.87%8.06%0.14%0.74%7.50%
Quick Ratio6.87%8.06%0.14%0.71%7.04%
Ownership Information
Institutional Ownership Percentage74.22%63.86%0.15%55.75%68.63%
Insider Ownership Percentage7.10%17.20%11.80%64.30%30.77%
Miscellaneous
Employees20979664130
Shares Outstanding36.78 million53.77 million387.72 million44.11 million34.01 million
Next Earnings Date11/5/2019 (Estimated)11/6/2019 (Estimated)10/22/2019 (Estimated)11/12/2019 (Estimated)11/14/2019 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
 Five Prime TherapeuticsCalithera BiosciencesCytoDynCerecorKala Pharmaceuticals

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel